Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, Frédérique, Cannon, Catherine, Barbour, Robin, Burke, Rae-Lyn, Games, Dora, Grajeda, Henry, Guido, Teresa, Hu, Kang, Huang, Jiping, Johnson-Wood, Kelly, Khan, Karen, Kholodenko, Dora, Lee, Mike, Lieberburg, Ivan, Motter, Ruth, Nguyen, Minh, Soriano, Ferdie, Vasquez, Nicki, Weiss, Kim, Welch, Brent, Seubert, Peter, Schenk, Dale, Yednock, Ted·2000·Nature Medicine
DOI 10.1038/78682

Cited by (1,003)

Items 501–600 of 1,003

  1. The Cerebral Proteopathies
    Lary C. Walker, Harry LeVine · 2000 · Molecular Neurobiology
  2. Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy
    Justin A. Legleiter, Dan L. Czilli, Bruce D. Gitter, Ronald Bradley Demattos, David M. Holtzman, Tomasz Kowalewski · 2003 · Journal of Molecular Biology
  3. Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
    Kristina Magnusson, Dag Sehlin, Stina Syvänen, Marie M. Svedberg, Ola Philipson, Linda Söderberg, Karin Tegerstedt, Mats Holmquist, Pär Gellerfors, Толмачев Владимир Максимилианович et al. · 2013 · Journal of Alzheimer s Disease
  4. Targeting of Monomer/Misfolded SOD1 as a Therapeutic Strategy for Amyotrophic Lateral Sclerosis
    H.-N. Liu, Sonja Tjostheim, K. DaSilva, D. Taylor, Beibei Zhao, Rishi Rakhit, M. Brown, Avijit Chakrabartty, JoAnne McLaurin, J. Robertson · 2012 · Journal of Neuroscience
  5. Anti-amyloid beta protein antibody passage across the blood–brain barrier in the SAMP8 mouse model of Alzheimer's disease: An age-related selective uptake with reversal of learning impairment
    William A. Banks, Susan A. Farr, John Edward Morley, Kathy M. Wolf, Valeria Geylis, Michael O Steinitz · 2007 · Experimental Neurology
  6. SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer' Disease: The Role of the Immune System in Clearance of Aβ from the Brain
    Delphine Boche, James A. R. Nicoll · 2008 · Brain Pathology
  7. Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma
    Amy B. Heimberger, Gary E. Archer, Laura E. Crotty Alexander, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, John Howard Sampson · 2002 · Neurosurgery
  8. Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease
    Wirths, Oliver, Erck, Christian, Martens, Henrik, Harmeier, Anja, Geumann, Constanze, Jawhar, Sadim, Kumar, Sathish, Multhaup, Gerd, Walter, Jochen, Ingelsson, Martin et al. · 2010 · Journal of Biological Chemistry
  9. Microglial Activation in Alzheimers Disease
    Johannes C. M. Schlachetzki, Michael Hüll · 2009 · Current Alzheimer Research
  10. Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease
    Florence Pasquier, Carl Sadowsky, Ann R Holstein, Ghislaine Le Prince, Yahong Peng, Nicholas M. Jackson, Nick C. Fox, Nzeera Ketter, Enchi Liu, J. Michael Ryan et al. · 2016 · Journal of Alzheimer s Disease
  11. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β-amyloid plaques in a mouse model of Alzheimer's disease
    Jianmin Zhang, Xiaobing Wu, Chuan Qin, Qi Jin, Shibin Ma, Huiyuan Zhang, Qingli Kong, Dongqing Chen, Denian Ba, Wei He · 2003 · Neurobiology of Disease
  12. The role of nucleotides in the neuron–glia communication responsible for the brain functions
    Kazuhide Inoue, Schuichi Koizumi, Makoto Tsuda · 2007 · Journal of Neurochemistry
  13. Immunotherapy for Alzheimer's disease
    Richard C. Dodel, Harald Juergen Hampel, Yansheng Du · 2003 · The Lancet Neurology
  14. Immunotherapy of malignant brain tumors
    Duane A. Mitchell, Peter Edward Fecci, John Howard Sampson · 2008 · Immunological Reviews
  15. Regulation of β-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor α
    Colin Kelly Combs, Patricia Bates, J. Colleen Karlo, Gary E. Landreth · 2001 · Neurochemistry International
  16. Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy
    Nina Movsesyan, Anahit Ghochikyan, Mikayel Mkrtichyan, Irina Petrushina, Hayk Davtyan, Purevdorj Baljinnyam Olkhanud, Elizabeth Head, Arya Biragyn, David H. Cribbs, Michael G. Agadjanyan · 2008 · PLoS ONE
  17. Immunotherapy for Alzheimer's disease
    Thomas Wısnıewskı, Fernando Goñi · 2014 · Biochemical Pharmacology
  18. Early pathologic amyloid induces hypersynchrony of BOLD resting‐state networks in transgenic mice and provides an early therapeutic window before amyloid plaque deposition
    Disha Shah, Jelle Praet, Amira Latif‐Hernandez, Corinna Höfling, Cynthia Anckaerts, Frédérique Bard, Markus Morawski, Jan R. Detrez, Els Prinsen, Alessandro Maria Villa et al. · 2016 · Alzheimer s & Dementia
  19. Structures of the Amyloid β-Peptides Aβ1–40 and Aβ1–42 as Influenced by pH and a d -Peptide
    Olujide O. Olubiyi, Birgit Strodel · 2012 · The Journal of Physical Chemistry B
  20. Lessons from the AN 1792 Alzheimer vaccine: lest we forget
    Stephen R. Robinson, Glenda M. Bishop, Hyoung‐gon Lee, Gerald W Münch · 2004 · Neurobiology of Aging
  21. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
    Francesco Panza, Vincenzo Solfrizzi, Bruno Pietro Imbimbo, Rosanna Tortelli, Andrea Santamato, Giancarlo Logroscino · 2014 · Expert Review of Clinical Immunology
  22. Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease
    Ken-ichiro Fukuchi, Kazuki Tahara, Hong‐Duck Kim, J. Adam Maxwell, Terry L. Lewis, Mary Ann Accavitti-Loper, Helen Kim, Selvarangan Ponnazhagan, Robert Lalonde · 2006 · Neurobiology of Disease
  23. Transgenic mouse models of Alzheimer's disease: How useful have they been for therapeutic development?
    Karen Duff · 2004 · Briefings in Functional Genomics and Proteomics
  24. Active immunotherapy options for Alzheimer’s disease
    Bengt G. Winblad, Ana Graf, Marie‐Emmanuelle Riviere, Niels Andreasen, J. Michael Ryan · 2014 · Alzheimer s Research & Therapy
  25. Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease
    Wang, Chang Yi, Finstad, Connie L., Walfield, Alan M., Sia, Charles, Sokoll, Kenneth K., Chang, Tseng-Yuan, Fang, Xin De, Hung, Chung Ho, Hutter-Paier, Birgit, Windisch, Manfred · 2007 · Vaccine
  26. Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease
    Rodríguez, J J, Witton, J, Olabarria, M, Noristani, H N, Verkhratsky, A · 2010 · Cell Death & Disease
  27. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography
    David James Brooks · 2009 · Movement Disorders
  28. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Francesco Panza, Giancarlo Logroscino, Bruno Pietro Imbimbo, Vincenzo Solfrizzi · 2014 · Current Opinion in Psychiatry
  29. Tau as a Therapeutic Target for Alzheimers Disease
    Allal Boutajangout, Einar M. Sigurdsson, P. K. Krishnamurthy · 2011 · Current Alzheimer Research
  30. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease
    Johanna M. Magga, Lakshman Puli, Rea Pihlaja, Katja M. Kanninen, Suvi Neulamaa, Tarja Malm, Wolfgang Härtig, Jens Grosche, Gundars Goldsteins, Heikki Tanila et al. · 2010 · Journal of Neuroinflammation
  31. An Update of Animal Models of Alzheimer Disease with a Reevaluation of Plaque Depositions
    Jung Eun Lee, Pyung‐Lim Han · 2013 · Experimental Neurobiology
  32. Marginal vitamin A deficiency facilitates Alzheimer’s pathogenesis
    Jiaying Zeng, Li Chen, Zhe Wang, Qian Chen, Zhen Fan, Hongpeng Jiang, Yili Wu, Lan Ren, Jie Chen, Tingyu Li et al. · 2017 · Acta Neuropathologica
  33. The JNK/c-Jun cascade and Alzheimer's disease
    Hitohi Okazawa, Steven Estus · 2002 · American Journal of Alzheimer s Disease & Other Dementias®
  34. Role of Interleukin-1 in Prion Disease-Associated Astrocyte Activation
    Julia Schultz, Anja Schwarz, Sabine Neidhold, Michael Burwinkel, Constanze Riemer, Dietrich Simon, Manfred Köpf, Markus Otto, Michael Baier · 2004 · American Journal Of Pathology
  35. Alzheimer's disease and the amyloid cascade hypothesis: ten years on
    Bernd Sommer · 2002 · Current Opinion in Pharmacology
  36. ABCA7 Mediates Phagocytic Clearance of Amyloid-β in the Brain
    YuHong Fu, Jen-Hsiang T. Hsiao, George Paxinos, Glenda Margaret Halliday, Woojin Scott Kim · 2016 · Journal of Alzheimer s Disease
  37. Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APP London Mice
    Helmut Jacobsen, Laurence Ozmen, Antonello Caruso, Robert Narquizian, Hans Hilpert, Björn Jacobsen, Dick Terwel, An Tanghe, Bernd Bohrmann · 2014 · Journal of Neuroscience
  38. Animal models of amyloid‐β‐related pathologies in Alzheimer’s disease
    Ola Philipson, Anna Lord, Astrid Gumucio, Paul W. O'Callaghan, Lars Lannfelt, Lars N. G. Nilsson · 2010 · FEBS Journal
  39. Multiple cellular and molecular mechanisms Are involved in human Aβ clearance by transplanted adult astrocytes
    Pihlaja, Rea, Koistinaho, Jari, Kauppinen, Riitta, Sandholm, Jouko, Tanila, Heikki, Koistinaho, Milla · 2011 · Glia
  40. Engineered antibodies: new possibilities for brain PET?
    Dag Sehlin, Stina Syvänen · 2019 · European Journal of Nuclear Medicine and Molecular Imaging
  41. Interplay Between Mitochondrial Oxidative Disorders and Proteostasis in Alzheimer’s Disease
    Emilio Llanos-González, Ángel Andres Henares-Chavarino, Cristina M. Pedrero-Prieto, Sonia García‐Carpintero, Javier Frontiñán-Rubio, Francisco Javier Sancho-Bielsa, Francisco Javier Alcain, Juan R. Peinado, Yoana Rabanal‐Ruiz, Mario Durán‐Prado · 2020 · Frontiers in Neuroscience
  42. Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid
    Donna M. Wilcock, Paul T. Jantzen, Qi Li, David Morgan, Marcia N. Gordon · 2006 · Neuroscience
  43. Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman
    Dennis J. Selkoe · 2003 · Neurochemical Research
  44. Microglia in Alzheimer's Disease: It's All About Context
    Weitz, Tara M., Town, Terrence · 2012 · International Journal of Alzheimer's Disease
  45. Intranasal therapeutic strategies for management of Alzheimer’s disease
    Sumeet Sood, Kunal Jain, K. Gowthamarajan · 2014 · Journal of drug targeting
  46. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches
    Parveen Salahuddin, Munazza Tamkeen Fatima, Ali S. Abdelhameed, Saima Nusrat, Rizwan Hasan Khan · 2016 · European Journal of Medicinal Chemistry
  47. Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease
    Sherry L. LaPorte, Sangeetha Subbarao Bollini, Thomas A. Lanz, Yasmina Noubia Abdiche, Alexander S. Rusnak, Wei-Hsien Ho, Dione T. Kobayashi, Ons Harrabi, Danielle C. Pappas, Erene W. Mina et al. · 2011 · Journal of Molecular Biology
  48. Amyloid Reduction by Amyloid- Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease
    Donna M. Wilcock, Nastaran Gharkholonarehe, William E. Van Nostrand, J. Davis, Michael Peter Vitek, Carol A. Colton · 2009 · Journal of Neuroscience
  49. Anti-oligomeric Aβ Single-chain Variable Domain Antibody Blocks Aβ-induced Toxicity Against Human Neuroblastoma Cells
    Andleeb Zameer, Srinath Kasturirangan, Sharareh Emadi, Sridevi V. Nimmagadda, Michael R. Sierks · 2008 · Journal of Molecular Biology
  50. AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils
    Jonathan S. Wall, Stephen J. Kennel, Angela D. Williams, Tina Richey, Alan C. Stuckey, Ying Huang, Sallie D. Macy, Robert L. Donnell, Robin Barbour, Peter A. Seubert et al. · 2012 · PLoS ONE
  51. Physiological Roles of Amyloid-?? and Implications for its Removal in Alzheimer???s Disease
    Bishop, Glenda M, Robinson, Stephen R · 2004 · Drugs & Aging
  52. Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
    Somin Kwon, Michiyo Iba, Changyoun Kim, Eliezer Masliah · 2020 · Neurotherapeutics
  53. Anti-Aβ1–11 Antibody Binds to Different β-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers
    Grigor Mamikonyan, Mihaela Necula, Mikayel Mkrtichyan, Anahit Ghochikyan, Irina Petrushina, Nina Movsesyan, Erene W. Mina, Anatoly B. Kiyatkin, Charles G. Glabe, David H. Cribbs et al. · 2007 · Journal of Biological Chemistry
  54. Role of high mobility group protein-1 (HMG1) in amyloid-β homeostasis
    Kazuyuki Takata, Yoshihisa Kitamura, Jun‐ichi Kakimura, Keiichi Shibagaki, Daiju Tsuchiya, Takashi Taniguchi, Mark A. Smith, George L. Perry, Shun Shimohama · 2003 · Biochemical and Biophysical Research Communications
  55. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease
    Rocío Pérez‐González, Consuelo Pascual, Desireé Antequera, Marta Bolós, Miriam Redondo, Daniel I. Pérez, Virginia Pérez‐Grijalba, Agnieszka Krzyzanowska, Manuel Sarasa, Carmen Gil et al. · 2013 · Neurobiology of Aging
  56. Disease-Modifying Therapies in Alzheimer???s Disease
    Michael H ll, Thomas Berger, Michael Thomas Heneka · 2006 · Drugs
  57. Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric Aβ Species in Amyloid Precursor Protein Transgenic Mice
    Irina Petrushina, Anahit Ghochikyan, Mikayel Mktrichyan, Gregory Mamikonyan, Nina Movsesyan, Hayk Davtyan, Archita J. Patel, Elizabeth Head, David H. Cribbs, Michael G. Agadjanyan · 2007 · Journal of Neuroscience
  58. Mice as models: Transgenic approaches and Alzheimer's disease
    Dora Games, Manuel Buttini, Dione T. Kobayashi, Dale Schenk, Peter A. Seubert · 2006 · Journal of Alzheimer s Disease
  59. Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
    Chakroborty, Shreaya, Stutzmann, Grace E. · 2014 · European Journal of Pharmacology
  60. Amyloid-β Immunotherapy for Alzheimers Disease
    Hongjun Fu, B. Liu, Jeffrey L. Frost, Cynthia Ann Lemere · 2010 · CNS & Neurological Disorders - Drug Targets
  61. Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores.
    Sage Arbor, Mike LaFontaine, Medhane G. Cumbay · 2016 · Europe PMC (PubMed Central)
  62. The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches
    Alice Drobny, Susy Prieto Huarcaya, Jan Philipp Dobert, Annika Kluge, Josina Bunk, Theresia Schlothauer, Friederike Zunke · 2022 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  63. Degradation of fibrillar forms of Alzheimer's amyloid β-peptide by macrophages
    Amitabha Majumdar, Haeyong Chung, Georgia Dolios, Rong Wang, Nikiya Asamoah, Peter Lobel, Frederick R. Maxfield · 2007 · Neurobiology of Aging
  64. Yin and Yang: complement activation and regulation in Alzheimer’s disease
    Yong Shen, Seppo Meri · 2003 · Progress in Neurobiology
  65. Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease
    Valentina Echeverrı́a, Alexandre Iarkov, Gjumrakch Aliev · 2016 · Progress in Neurobiology
  66. Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
    Bruno Pietro Imbimbo, Simone Ottonello, Vincenza Frisardi, Vincenzo Solfrizzi, Antonio Greco, Davide Seripa, Alberto Pilotto, Francesco Panza · 2012 · Expert Review of Clinical Immunology
  67. Bapineuzumab
    Geoffrey A. Kerchner, Adam L. Boxer · 2010 · Expert Opinion on Biological Therapy
  68. CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease
    Tomomi Kiyota, Howard Eliot Gendelman, Robert A. Weir, E. Elizabeth Higgins, Gang Zhang, Mohit Jain · 2012 · Neurobiology of Aging
  69. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer’s disease
    J. Steven Jacobsen, Peter H. Reinhart, Menelas N. Pangalos · 2005 · NeuroRx
  70. Efflux of human and mouse amyloid β proteins 1–40 and 1–42 from brain: impairment in a mouse model of alzheimer's disease
    William A. Banks, S.M Robinson, S Verma, John Edward Morley · 2003 · Neuroscience
  71. Autoantibodies to Redox-modified Oligomeric Aβ Are Attenuated in the Plasma of Alzheimer's Disease Patients
    Robert D. Moir, Katya A. Tseitlin, Stephanie J. Soscia, Bradley T. Hyman, Michael C. Irizarry, Rudolph E. Tanzi · 2005 · Journal of Biological Chemistry
  72. Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease
    Hideo Hara, Alon Monsonego, Katsutoshi Yuasa, Kayo Adachi, Xiao Xiao, Shin’ichi Takeda, Keikichi Takahashi, Howard L. Weiner, Takeshi Tabira · 2004 · Journal of Alzheimer s Disease
  73. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
    Amy B. Heimberger, John Howard Sampson · 2009 · Expert Opinion on Biological Therapy
  74. In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques
    Joseph F. Poduslo, Muthu Ramakrishnan, Silvina S. Holasek, Marina Ramı́rez-Alvarado, Karunya K. Kandimalla, Emily J. Gilles, Geoffry L. Curran, Thomas M. Wengenack · 2007 · Journal of Neurochemistry
  75. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases
    Douglas G. Walker, L-F Lue · 2005 · Journal of Neuroscience Research
  76. CD45 Deficiency Drives Amyloid-β Peptide Oligomers and Neuronal Loss in Alzheimer's Disease Mice
    Yuyan Zhu, Huayan Hou, Kavon P. Rezai-Zadeh, Brian N. Giunta, Amanda Ruscin, Carmelina Gemma, Jingji Jin, Natasa Dragicevic, Patrick C. Bradshaw, Suhail Rasool et al. · 2011 · Journal of Neuroscience
  77. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin
    Jeffrey N. Higaki, Avijit Chakrabartty, Natalie J. Galant, Kevin C. Hadley, Bradley Hammerson, Tarlochan Nijjar, Ronald Torres, Jose R. Tapia, Joshua Salmans, Robin Barbour et al. · 2016 · Amyloid
  78. CpG‐containing oligodeoxynucleotide promotes microglial cell uptake of amyloid β 1–42 peptide by up‐regulating the expression of the G‐protein‐coupled receptor mFPR2
    Iribarren, Pablo, Chen, Keqiang, Hu, Jinyue, Gong, Wanghua, Cho, Edward H., Lockert, Stephen, Uranchimeg, Badarch, Wang, Ji Ming · 2005 · The FASEB Journal
  79. Melanocortin-4 receptor activation stimulates hypothalamic brain-derived neurotrophic factor release to regulate food intake, body temperature and cardiovascular function
    Nicholson, J. R., Peter, J.‐C., Lecourt, A.‐C., Barde, Y.‐A., Hofbauer, K. G. · 2007 · Journal of Neuroendocrinology
  80. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid
    Stalder, M, Deller, T, Staufenbiel, M, Jucker, M · 2001 · Neurobiology of Aging
  81. Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
    Kasia Lobello, J. Michael Ryan, Enchi Liu, Gregory A. Rippon, Ronald S. Black · 2012 · International Journal of Alzheimer s Disease
  82. Microglial Immunoreceptor Tyrosine-Based Activation and Inhibition Motif Signaling in Neuroinflammation
    Linnartz, Bettina, Wang, Yiner, Neumann, Harald · 2010 · International Journal of Alzheimer's Disease
  83. Number of A β Inoculations in APP+PS1 Transgenic Mice Influences Antibody Titers, Microglial Activation, and Congophilic Plaque Levels
    Donna M. Wilcock, Marcia N. Gordon, Kenneth E. Ugen, Paul E. Gottschall, Giovanni DiCarlo, Chad A. Dickey, Kristal W. Boyett, Paul T. Jantzen, Karen E. Connor, Jason Melachrino et al. · 2001 · DNA and Cell Biology
  84. A translational platform PBPK model for antibody disposition in the brain
    Hsueh-Yuan Chang, Shengjia Wu, Guy M. L. Meno‐Tetang, Dhaval K. Shah · 2019 · Journal of Pharmacokinetics and Pharmacodynamics
  85. Antibody to Amyloid β Protein Alleviates Impaired Acquisition, Retention, and Memory Processing in SAMP8 Mice
    John Edward Morley, Susan A. Farr, James F. Flood · 2002 · Neurobiology of Learning and Memory
  86. Reduction of Amyloid Angiopathy and Aβ Plaque Burden after Enriched Housing in TgCRND8 Mice
    Oliver Ambrée, Uwe Leimer, Arne Herring, Nicole Goertz, Norbert Sachser, Michael Thomas Heneka, Werner Paulus, Kathy Keyvani · 2006 · American Journal Of Pathology
  87. Attenuation of β-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: Role of sialic acid attachment
    Dhara A. Patel, James E. Henry, Theresa A. Good · 2007 · Brain Research
  88. Vasoactive intestinal peptide protects against β‐amyloid‐induced neurodegeneration by inhibiting microglia activation at multiple levels
    Mario Delgado, Nieves Varela, Elena González‐Rey · 2008 · Glia
  89. Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer’s disease by EFRH-phage immunization
    Dan Frenkel, Ilse Dewachter, Fred VAN LEUVEN, Beka Solomon · 2003 · Vaccine
  90. Open questions for Alzheimer’s disease immunotherapy
    Todd Eliot Golde · 2014 · Alzheimer s Research & Therapy
  91. Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in T H 1 and T H 17 Versions of Experimental Autoimmune Encephalomyelitis
    Grant, Jacqueline L., Ghosn, Eliver Eid Bou, Axtell, Robert C., Herges, Katja, Kuipers, Hedwich F., Woodling, Nathan S., Andreasson, Katrin, Herzenberg, Leonard A., Herzenberg, Leonore A., Steinman, Lawrence · 2012 · Science Translational Medicine
  92. CR1 in Alzheimer's Disease
    Xi‐Chen Zhu, Jin‐Tai Yu, Teng Jiang, Ping Wang, Lei Cao, Lan Tan · 2014 · Molecular Neurobiology
  93. Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
    Abdelrahman Ibrahim Abushouk, Ahmed Elmaraezy, Amro D. Aglan, Reham Salama, Samar Fouda, Rana Fouda, Ammar M. AlSafadi · 2017 · BMC Neurology
  94. Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody
    Stina Syvänen, Greta Hultqvist, Tobias Gustavsson, Astrid Gumucio, Hanna Laudon, Linda Söderberg, Martin Ingelsson, Lars Lannfelt, Dag Sehlin · 2018 · Alzheimer s Research & Therapy
  95. Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
    Anne‐Cathrine S. Vogt, Gary T. Jennings, Mona Omar Mohsen, Monique Vogel, Martin F. Bachmann · 2023 · International Journal of Molecular Sciences
  96. Signal Regulatory Protein-β1
    Sadanand M. Gaikwad, Sergey Larionov, Yiner Wang, Holger Dannenberg, Takashi Matozaki, Alon Monsonego, Dietmar Rudolf Thal, Harald Neumann · 2009 · American Journal Of Pathology
  97. Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
    Greg M. Cole, Sally Ann Frautschy · 2010 · CNS & Neurological Disorders - Drug Targets
  98. Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier
    Roberto Villaseñor, Laurence Ozmen, Nadia Messaddeq, Fiona Grüninger, Hansruedi Loetscher, Annika Keller, Christer Betsholtz, Per‐Ola Freskgård, Ludovic Collin · 2016 · Scientific Reports
  99. Autoantibody-catalyzed Hydrolysis of Amyloid β Peptide
    Hiroaki Taguchi, Stephanie A. Planque, Yasuhiro Nishiyama, Jindrich Symersky, Stéphane Boivin, Paul Szabo, Robert Paul Friedland, Paul A. Ramsland, Allen B. Edmundson, Marc E. Weksler et al. · 2007 · Journal of Biological Chemistry
  100. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine
    Cynthia Ann Lemere · 2009 · Progress in brain research